SGLT2 Inhibitors Do Not Increase Amputation Risk in Diabetic Foot Ulcer: Study Reveals Significant Mortality Benefit
Key Highlights
SGLT2 inhibitor therapy does not increase 1-year amputation risk in patients with diabetic foot ulcers, challenging prior concerns about potential harm. Patients receiving SGLT2 inhibitors demonstrated a dramatic reduction in 1-year mortality (1.1% vs 9.2%, P = 0.009), representing an 88% relative reduction in death risk. Wound healing time was significantly shorter in the SGLT2 inhibitor group, with a mean difference of 44 days (136.5 vs 181.2 days, P = 0.04). The findings provide important real-world evidence for the safety profile of these agents in a high-risk population.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.